developments in the use of bispecific antibodies in myeloma and challenges in this space
Published 1 year ago • 331 plays • Length 7:05Download video MP4
Download video MP3
Similar videos
-
3:49
the challenges in developing bispecific antibodies for non-hodgkin lymphoma
-
4:02
an overview of bispecifics in r/r myeloma and their integration into the treatment landscape
-
3:37
bispecific antibodies in multiple myeloma: their current role and the future
-
2:22
outcomes and management of patients with r/r myeloma who progress on bispecific antibodies
-
1:45
the advent of bispecific antibodies for multiple myeloma
-
1:20
a comparison of bispecific antibodies emerging in multiple myeloma
-
1:29
insights into the biology of high-risk myeloma and advances being made in this space
-
4:04
the future of myeloma treatment and the possibility of cure
-
6:17
myeloma made simple: bispecific antibodies made simple | bispecific antibodies for myeloma treatment
-
47:52
development of multi-specific therapeutic antibodies via computer aided design
-
1:23
investigating bispecific antibodies in high-risk smoldering myeloma: the immunoprism platform study
-
2:50
phase i study of abbv383, a novel bcmaxcd3 bispecific antibody, in r/r multiple myeloma
-
2:00
the success story of bispecific and trispecific antibodies
-
1:37
the promise of elranatamab and other bispecifics in the treatment of myeloma
-
2:56
the exciting future of bispecific antibodies
-
2:41
an overview of the latest advances in hematology
-
3:03
developments in multiple myeloma - immunotherapy and personalized medicine
-
6:13
phase i study of forimtamig, a gprc5dxcd3 bispecific antibody, in r/r multiple myeloma
-
1:33
sequencing and the management of adverse events when administering bispecifics for myeloma
-
0:57
insights into new bite developments in multiple myeloma
-
1:03
using bispecific antibodies instead of chemotherapy to reach pre-transplant remission in b-all
-
1:55
updates at ash 2020 on bispecific antibodies in mm